| 0 (N=2464) |
1 (N=17) |
2 (N=20) |
3 (N=185) |
Overall (N=2686) |
|
|---|---|---|---|---|---|
| Sex | |||||
| Kvinna | 1677 (68.1%) | 13 (76.5%) | 15 (75.0%) | 132 (71.4%) | 1837 (68.4%) |
| Man | 785 (31.9%) | 4 (23.5%) | 5 (25.0%) | 53 (28.6%) | 847 (31.5%) |
| Missing | 2 (0.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (0.1%) |
| Age | |||||
| Mean (SD) | 42.1 (11.7) | 36.4 (8.67) | 39.2 (10.0) | 40.8 (10.9) | 41.9 (11.6) |
| Median [Min, Max] | 42.0 [9.70, 77.1] | 36.1 [23.1, 52.3] | 41.8 [23.0, 56.5] | 40.2 [16.0, 74.0] | 41.9 [9.70, 77.1] |
| Missing | 3 (0.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (0.1%) |
| EDSS | |||||
| Mean (SD) | 2.68 (1.98) | 2.11 (0.984) | 2.44 (2.44) | 2.65 (1.95) | 2.68 (1.98) |
| Median [Min, Max] | 2.00 [0, 9.00] | 2.00 [0, 4.00] | 1.75 [0, 8.50] | 2.00 [0, 8.00] | 2.00 [0, 9.00] |
| Missing | 505 (20.5%) | 3 (17.6%) | 8 (40.0%) | 42 (22.7%) | 558 (20.8%) |
| BMI | |||||
| Mean (SD) | 25.8 (5.43) | 25.2 (7.29) | 25.2 (6.24) | 24.5 (5.33) | 25.7 (5.46) |
| Median [Min, Max] | 24.7 [13.7, 61.6] | 23.3 [18.4, 46.3] | 22.0 [18.8, 37.9] | 23.4 [17.4, 56.1] | 24.6 [13.7, 61.6] |
| Missing | 1047 (42.5%) | 2 (11.8%) | 6 (30.0%) | 73 (39.5%) | 1128 (42.0%) |
| MS type | |||||
| NA | 4 (0.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (0.1%) |
| PPMS | 130 (5.3%) | 0 (0%) | 4 (20.0%) | 10 (5.4%) | 144 (5.4%) |
| RRMS | 1767 (71.7%) | 13 (76.5%) | 14 (70.0%) | 137 (74.1%) | 1931 (71.9%) |
| SPMS | 563 (22.8%) | 4 (23.5%) | 2 (10.0%) | 38 (20.5%) | 607 (22.6%) |
| Center | |||||
| Gothenburg | 394 (16.0%) | 4 (23.5%) | 4 (20.0%) | 22 (11.9%) | 424 (15.8%) |
| Northern | 456 (18.5%) | 1 (5.9%) | 4 (20.0%) | 32 (17.3%) | 493 (18.4%) |
| Stockholm CFN Karolinska | 1313 (53.3%) | 8 (47.1%) | 12 (60.0%) | 108 (58.4%) | 1441 (53.6%) |
| Stockholm Danderyd | 301 (12.2%) | 4 (23.5%) | 0 (0%) | 23 (12.4%) | 328 (12.2%) |
| Previous treatment | |||||
| Cladribine | 37 (1.5%) | 0 (0%) | 0 (0%) | 5 (2.7%) | 42 (1.6%) |
| Fumarate | 209 (8.5%) | 3 (17.6%) | 1 (5.0%) | 12 (6.5%) | 225 (8.4%) |
| Glatiramer_acetate | 100 (4.1%) | 0 (0%) | 1 (5.0%) | 5 (2.7%) | 106 (3.9%) |
| Interferon | 477 (19.4%) | 2 (11.8%) | 4 (20.0%) | 33 (17.8%) | 516 (19.2%) |
| Natalizumab | 491 (19.9%) | 2 (11.8%) | 4 (20.0%) | 43 (23.2%) | 540 (20.1%) |
| Other | 101 (4.1%) | 3 (17.6%) | 1 (5.0%) | 15 (8.1%) | 120 (4.5%) |
| Other Anti-CD20 | 44 (1.8%) | 0 (0%) | 1 (5.0%) | 4 (2.2%) | 49 (1.8%) |
| S1PR-inhibitors | 203 (8.2%) | 0 (0%) | 0 (0%) | 10 (5.4%) | 213 (7.9%) |
| Teriflunomide | 41 (1.7%) | 0 (0%) | 0 (0%) | 2 (1.1%) | 43 (1.6%) |
| Missing | 761 (30.9%) | 7 (41.2%) | 8 (40.0%) | 56 (30.3%) | 832 (31.0%) |
| IgG | |||||
| Mean (SD) | 9.84 (2.19) | 9.58 (2.25) | 9.03 (1.84) | 9.90 (2.04) | 9.84 (2.18) |
| Median [Min, Max] | 9.67 [2.30, 20.6] | 9.69 [6.51, 14.1] | 8.67 [6.40, 12.5] | 9.80 [5.31, 16.3] | 9.67 [2.30, 20.6] |
| Missing | 19 (0.8%) | 0 (0%) | 0 (0%) | 0 (0%) | 19 (0.7%) |
| Neutrophils | |||||
| Mean (SD) | 4.14 (1.26) | 3.95 (0.995) | 4.12 (1.22) | 2.97 (1.27) | 4.06 (1.29) |
| Median [Min, Max] | 3.93 [1.85, 15.2] | 4.05 [1.85, 5.44] | 4.02 [2.38, 6.46] | 2.60 [1.03, 8.21] | 3.87 [1.03, 15.2] |